Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies

Blood (2024) 144 (Supplement 1): 2078.

https://doi.org/10.1182/blood-2024-207532

Published: 2024

Journal Articles

LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort

Jennifer A. Woyach, Danielle M. Brander, Boyu Hu, Kerry A. Rogers, Zulfa Omer, Deborah M. Stephens, Andrea Sitlinger, Fenlai Tan, Yi Chen, Stephen P. Anthony, Yu Chen, Kewei Shang, John C. Byrd

Blood (2024) 144 (Supplement 1): 4622.

https://doi.org/10.1182/blood-2024-205775

Published: 2024

Journal Articles

Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects

Anthony G Mansour, Ying Huang, Aseel Alsouqi, Adam S Kittai, John C. Byrd, Michael R. Grever, Cecelia Miller, Gerard Lozanski, Mollie Moran, Margaret S. Lucas, Swetha Suresh, Cara Grantier, Corinne Hoffman, Mark Reid, Kerry A. Rogers, Seema A Bhat, Jennifer A. Woyach

Blood (2024) 144 (Supplement 1): 4629.

https://doi.org/10.1182/blood-2024-199676

Published: 2024

Journal Articles

Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2024-203522

Published: 2024

Journal Articles

Prospective Randomized Phase 2 Study of Acalabrutinib + Obinutuzumab or Venetoclax in Previously Untreated CLL

Adam S Kittai, Ying Huang, Seema A Bhat, Michael R. Grever, Swetha Suresh, Gerard Lozanski, Mollie Moran, Megan Nussbaum, Jennifer A. Woyach, Kerry A. Rogers

Blood (2024) 144 (Supplement 1): 4634.1.

https://doi.org/10.1182/blood-2024-199561

Published: 2024

Journal Articles

TP53 Gain-of-Function Mutants Display Unique Transcriptional Profiles in Chronic Lymphocytic Leukemia

Charmelle D. Williams, Suresh Satpati, Janani Ravikrishnan, Bailey Slawin, Daisy Y. Diaz Rohena, Palaniraja Thandapani, Kerry A. Rogers, Seema A. Bhat, Kunal Rai, Jennifer A. Woyach, Deepa Sampath

Blood (2024) 144 (Supplement 1): 6757.

https://doi.org/10.1182/blood-2024-199814

Published: 2024

Journal Articles

Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy

Blood (2024) 144 (Supplement 1): 5099.

https://doi.org/10.1182/blood-2024-198742

Published: 2024

Journal Articles

Non-V600E BRAF Gene Alterations in Hairy Cell Leukemia

Evgeny Arons, Chin-Hsien Tai, Suraj Joshi, Yuelin Liu, Chi-ping Day, Mark Raffeld, Liqiang Xi, Hong Zhou, Mory Gould, Isaac Shpilman, Christopher C. Oakes, Seema A Bhat, Michael R. Grever, Kerry A. Rogers, Hao-Wei Wang, Constance M. Yuan, Cenk Sahinalp, Robert J. Kreitman

Blood (2024) 144 (Supplement 1): 1586.

https://doi.org/10.1182/blood-2024-204016

Published: 2024

Journal Articles

Clinical Characteristics and Outcome in a Cohort of CLL Patients with BTK T474 Gatekeeper Mutation

Zulfa Omer, Max Yano, Jayesh Rai, Joyce Chen, Jennifer A. Woyach, Seema A. Bhat, Michael R. Grever, Dan Jones, Kerry A. Rogers, John C. Byrd

Blood (2024) 144 (Supplement 1): 1875.

https://doi.org/10.1182/blood-2024-209336

Published: 2024

Journal Articles

A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL

Blood (2024) 144 (Supplement 1): 3245.

https://doi.org/10.1182/blood-2024-205668

Published: 2024

Journal Articles

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

Blood (2024) 143 (16): 1616–1627.

https://doi.org/10.1182/blood.2023021959

Published: 2024

Includes: Supplemental data

Journal Articles

Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168

Blood (2023) 142 (Supplement 1): 416.

https://doi.org/10.1182/blood-2023-178259

Published: 2023

Journal Articles

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter's Transformation: An International Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 108.

https://doi.org/10.1182/blood-2023-180858

Published: 2023

Journal Articles

Initial Results of a Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL

Kerry A Rogers, Eric McLaughlin, Lai Wei, Seema A Bhat, Arianna Crouse, Michael R. Grever, Dan Jones, Adam S Kittai, Gerard Lozanski, Mollie Moran, Mark Reid, Ellen J Sass, Swetha Suresh, John C. Byrd, Jennifer A. Woyach

Blood (2023) 142 (Supplement 1): 1899.

https://doi.org/10.1182/blood-2023-180294

Published: 2023

Journal Articles

Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study

Andrea Visentin, Enrico Gaffo, Moritz Furstenau, Jennifer A. Woyach, Panagiotis Baliakas, Kerry A Rogers, Cecelia Miller, Claudia Haferlach, Karla Plevova, David Graham Oscier, Zadie Davis, Florence Nguyen Khac, Eleonora Roncaglia, Gian Matteo Rigolin, Anastasia Athanasiadou, Fanny Baran-Marszak, Alberto Valiente, Maria Jose Terol, Pau Abrisqueta, Blanca Espinet, Anna Puiggros, Annalisa Martines, Laura Bonaldi, Francesca Romana Mauro, Lydia Scarfo, Thomas Chatzikonstantinou, Eugen Tausch, Karl Anton Kreuzer, Arnon P. Kater, Francesc Bosch, Michael Doubek, Panayiotis Panayiotidis, Olga Kalashnikova, Federica Frezzato, Monica Facco, Valeria Ruocco, Alessia Buratin, Silvia Orsi, Alessandro Cellini, Francesco Angotzi, Chiara Adele Cavarretta, Ivan Zatta, Andrea Serafin, Robin Foa, Barbara F. Eichhorst, Antonio Cuneo, Kostas Stamatopoulos, Paolo Ghia, Stefania Bortoluzzi, Livio Trentin

Blood (2023) 142 (Supplement 1): 3275.

https://doi.org/10.1182/blood-2023-174569

Published: 2023

Journal Articles

Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL

Blood (2023) 142 (Supplement 1): 5149.

https://doi.org/10.1182/blood-2023-173992

Published: 2023

Journal Articles

Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 497.

https://doi.org/10.1182/blood-2023-182114

Published: 2023

Journal Articles

Comparative Effectiveness of Ibrutinib Flexible Dosing Treatment Strategies on Time to Next Treatment in a Largely Community-Based Claims Database: A Target Trial Emulation Study

Nilanjan Ghosh, Ruibin Wang, Zhijie Ding, Jinghua He, Alex Bokun, Heena Mavani, Zaina P Qureshi, Kerry A Rogers

Blood (2023) 142 (Supplement 1): 270.

https://doi.org/10.1182/blood-2023-187743

Published: 2023

Journal Articles

Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation

Nilanjan Ghosh, Zaina P Qureshi, Zhijie Ding, Marie-Helene Lafeuille, Bruno Emond, Priyanka Gogna, Bronwyn Moore, Patrick Lefebvre, Alex Bokun, Heena Mavani, Kerry A Rogers

Blood (2023) 142 (Supplement 1): 1915.

https://doi.org/10.1182/blood-2023-186284

Published: 2023

Journal Articles

T Cell Dysfunction and Exhaustion in Patients with CLL: The Impact of Long Term Ibrutinib Treatment

Shanmugapriya Thangavadivel, Charlene Mao, Meixiao Long, Shrilekha Misra, Samon Benrashid, Britten Gordon, Alexander He, Tzung-Huei Lai, Kerry A Rogers, Seema A Bhat, Adam S Kittai, John C. Byrd, Jennifer A. Woyach

Blood (2023) 142 (Supplement 1): 4631.

https://doi.org/10.1182/blood-2023-189755

Published: 2023

NARROW

Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies

LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort

Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects

Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia

Prospective Randomized Phase 2 Study of Acalabrutinib + Obinutuzumab or Venetoclax in Previously Untreated CLL

TP53 Gain-of-Function Mutants Display Unique Transcriptional Profiles in Chronic Lymphocytic Leukemia

Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy

Non-V600E BRAF Gene Alterations in Hairy Cell Leukemia

Clinical Characteristics and Outcome in a Cohort of CLL Patients with BTK T474 Gatekeeper Mutation

A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter's Transformation: An International Multicenter Retrospective Study

Initial Results of a Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL

Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study

Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL

Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study

Comparative Effectiveness of Ibrutinib Flexible Dosing Treatment Strategies on Time to Next Treatment in a Largely Community-Based Claims Database: A Target Trial Emulation Study

Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation

T Cell Dysfunction and Exhaustion in Patients with CLL: The Impact of Long Term Ibrutinib Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only